Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide plus metformin versus premixed insulin aspart plus metformin in inadequately controlled type 2 diabetes
2006-001938-41Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of exenatide and biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Glycemic control and Hypoglycemia incidence. Started Nov 2006; status: completed.
02
Drugs
exenatidebiphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-001938-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001938-41.